Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma”

14 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 14 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06586294
What this trial is testing

Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Akeso 294
Testing effectiveness (Phase 2)Ended earlyNCT05207722
What this trial is testing

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Who this might be right for
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Celularity Incorporated 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT05941481
What this trial is testing

Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
Jiangsu Cancer Institute & Hospital 21
Testing effectiveness (Phase 2)Looking for participantsNCT06196697
What this trial is testing

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Harbin Medical University 50
Large-scale testing (Phase 3)Not Yet RecruitingNCT06093425
What this trial is testing

Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Who this might be right for
Gastric CancerGastroesophageal-junction CancerAdvanced Cancer
Suzhou Transcenta Therapeutics Co., Ltd. 820
Testing effectiveness (Phase 2)Looking for participantsNCT06985602
What this trial is testing

Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ

Who this might be right for
Gastroesophageal AdenocarcinomaGastric Adenocarcinoma
Jiangsu Cancer Institute & Hospital 30
Large-scale testing (Phase 3)Study completedNCT05008783
What this trial is testing

AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Akeso 610
Not applicableLooking for participantsNCT07389876
What this trial is testing

Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma

Who this might be right for
Gastric CancerSecond-line Treatment
Fudan University 250
Testing effectiveness (Phase 2)Ended earlyNCT05161572
What this trial is testing

Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer

Who this might be right for
Stomach NeoplasmsEsophagogastric Junction DisorderNeoadjuvant Therapy+5 more
Fudan University 6
Large-scale testing (Phase 3)Looking for participantsNCT07152405
What this trial is testing

BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd. 490
Testing effectiveness (Phase 2)UnknownNCT05218148
What this trial is testing

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Who this might be right for
HER2-positiveLocally Advanced Solid TumorImmunotherapy+4 more
Aiping Zhou 44
Testing effectiveness (Phase 2)Study completedNCT03941873
What this trial is testing

Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

Who this might be right for
Carcinoma, HepatocellularGastric/Gastroesophageal Junction Cancer
BeiGene 111
Testing effectiveness (Phase 2)Study completedNCT03281369
What this trial is testing

Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Who this might be right for
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Hoffmann-La Roche 214
Testing effectiveness (Phase 2)Looking for participantsNCT06939452
What this trial is testing

A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression

Who this might be right for
Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Yongxu Jia 37